


Cancertrack™

**Blood based liquid biopsies for all
solid organ tumors**



LIQUID BIOPSIES
cancertrack™
NON-INVASIVE INTELLIGENT MULTI CO-ORDINATE

**DATAR
CANCER GENETICS**




About Cancertrack™

Cancertrack™ is a non-invasive blood based investigation that detects circulating tumor cells (CTCs) and cancer derived biomarkers with ultra-high precision, specificity and reliability. Cancertrack™ can be used to monitor the disease / recurrence or changes in the tumor characteristics, as often as necessary, without the cost, risk and consequences of radiation from scans, hospitalisation, anaesthesia or painful surgical biopsies.

Features of Cancertrack™

- Multi-coordinate and multidimensional probes to track down CTC / DNA / RNA released by cancer cells in the patient's blood
- Unique, unprecedented capability to detect cancerous activity
- Enables real-time rapid response to the dynamic molecular profile of a patient's cancer
- Safe, sure, simple and cost-effective
- Non-invasive blood test
- Not dependent on availability of tissue
- Tests all active disease sites
- Limit of detection is 0.1% Mutant Allele Frequency
- Far more powerful than conventional biopsy
- Extensive coverage of NCCN recommended biomarkers

Analytes




ctDNA: circulating, cell-free tumor DNA
mRNA: messenger RNA


miRNA: micro RNA
SNV: Single Nucleotide Variations (Point Mutations)

InDels: Insertions and Deletions
NCCN: National Comprehensive Cancer Network


Suitable for




Every person who has been diagnosed with cancer, as a supplement to conventional biopsy for a more robust molecular diagnosis and baseline measurement of cell-free tumor DNA before initiation of therapy



Every patient who is in remission / a cancer survivor and needs monitoring




Every patient who is under treatment for cancer



Every patient in whom the cancer is not responding satisfactorily to "Standard of Care" therapy

Keeping track of cancer is very critical

Cancer is best managed by a treatment plan that stays one step ahead of the tumor. However, conventional techniques such as imaging or scans can take more than 3 months to detect whether or not the treatment is working or it has failed. That's why, it is important to determine as quickly as possible if the cancer is responding to the therapy or is progressing. This information is now available through Cancertrack™.



FAQ's



How is Cancertrack™ validated?

Cancertrack™ has been validated clinically on several hundred samples and the process validation meets and exceeds the claimed sensitivity and specificity. Our laboratory is accredited by ISO 9001:2015, ISO 15189: 2012 and ISO 27001:2013, besides its compliance to “The College of American Pathologists” guidelines. All Cancertrack™ reports are reviewed by our experienced and qualified Molecular Tumor Board comprising of experts in the field. Our counsellors and experts are available for ongoing support.



Why is early detection of molecular dynamics of cancer critical?

The rapid and continuous evolution of the molecular profile of tumors results in tumor heterogeneity, which confers significant survival benefits on the tumor. Cancertrack unravels these molecular features in real time to identify critical signs linked to recurrence or emerging drug resistance as well as novel vulnerabilities, which empowers the treating clinician to avail optimum treatment strategies to intercept such cancers in a timely manner.



How frequently is it necessary to do the test?

Cancertrack™ should ideally be performed at every important milestone in the fight against cancer and especially when the tumor has disappeared from the conventional imaging / patient is under follow-up for recurrence monitoring.



What are the limitations of Cancertrack™?

While Cancertrack™ is extremely robust and multidimensional, like every molecular diagnostic technique, constraints naturally arising due to biological function in an individual patient may impact performance. However, such events are usually averaged out in sequential testing.

Sample Requirement :- 15-20 ml blood in DGL tubes

Turn Around Time (TAT) :- 2 weeks from receipt of the sample

Contact us:

✉ info-eu@datarpgx.com
🌐 datarpgx.com



DATAR
CANCER GENETICS